Cited by 110Extracellular vesicles in diseaseNanoparticle-Based Drug DeliveryRNA Interference and Gene Delivery

The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index; 5 of the 120 sources its claims cite were checked for support.

The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System

Open access

Abstract

Drug delivery system (DDS) realizes the drug delivery process through the drug carrier. As an important part of DDS, the selection of the drug carrier material is extremely critical, which requires the carrier material to possess excellent biocompatibility and targeting and not affect the pharmacological action of the drug. As one of the endogenous extracellular vesicles, exosomes are 30–100 nm in diameter, which are considered a new generation of a natural nanoscale delivery system. Exosomes secreted by different types of cells carry signaling molecules (such as proteins and nucleic acid) playing an important role in cell behaviors. Owing to their ability to specialize in intercellular communication, exosomes provide a distinctive method to deliver therapeutic drugs to target cells. In this concept, exosomes as the natural liposomes carry endogenous biomolecules, have excellent biocompatibility, and could be loaded with cargo both in vivo and in vitro. In addition, modifications by genetic and/or chemical engineering to part of the exosome surface or complement the desired natural effect may enhance the targeting with drug loading capability. Notably, exosomes weakly react with serum proteins prolonging cargo half-life. Overall, exosomes as natural carriers integrate the superiority of synthetic nanocarriers and cellular communication while precluding their limitations, which provides novel and reliable methods for drug delivery and treatment. Our review focuses on the therapeutic potentials and clinical values of exosomes as a carrier of drug delivery system in multiple diseases, including cancer, nervous, immune, and skeletal system diseases.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

Exosomes are 30–100 nm endogenous extracellular vesicles that can serve as natural drug delivery carriers because of their biocompatibility, cargo-loading capacity, and engineerable targeting. This narrative review summarizes preclinical and clinical evidence for exosome-based delivery across cancer, neurological, autoimmune, skeletal, cardiovascular, urinary, cutaneous, and metabolic diseases, while emphasizing that clinical translation remains limited by manufacturing, standardization, and in vivo validation gaps.

Key findings

  • Exosomes are 30–100 nm biphospholipid vesicles rich in lipids, proteins, DNA, noncoding RNA, mRNA, and other active molecules; they can be loaded in vivo or in vitro and surface-modified by genetic and/or chemical engineering to improve targeting.
  • The review reports therapeutic applications in multiple disease areas, including cancer (e.g., Survivin-T34A with gemcitabine in pancreatic cancer, PTEN mRNA in glioma, miR-379 in breast cancer, PTX, cisplatin, doxorubicin, CRISPR/Cas9), neurological disease (e.g., siRNA delivery across the BBB, dopamine-loaded exosomes in Parkinson’s disease), autoimmune disease, skeletal disease, cardiovascular disease, urinary system disease, cutaneous disease, and metabolic disease.
  • In autoimmune disease, exosome-encapsulated methotrexate from MSCs showed better retention and a 10-fold inhibition of inflammation compared with methotrexate alone.
  • The first cancer diagnostic product based on exosome miRNA body fluid biopsy, ExoDx Lung (ALK), was launched in 2016 and could detect EML4-ALK mutations in non-small cell lung cancer patients in real time.

Methods

  • Narrative review focusing on the therapeutic potential and clinical significance of exosomes as carriers in drug delivery systems, with emphasis on homologous exosomes.
  • Evidence is drawn from cited preclinical and clinical studies and organized by disease category, including cancer, nervous, immune, skeletal, cardiovascular, urinary, cutaneous, and metabolic diseases.
  • Main synthesis is thematic, covering exosome formation, loading and modification strategies, advantages over synthetic carriers, and disease-specific applications; no systematic search strategy, inclusion criteria, or meta-analysis is described.

Limitations

  • The paper states that most research on exosome carriers remains in the in vitro stage; manufacture, purification, storage, stability duration, loading efficiency, and dosage still require optimization, and off-target effects are not fully prevented by surface modification.
  • The paper states that standardized testing for exosome-delivered drugs is lacking, few studies investigate the ultimate fate of exosomes, and isolation techniques such as NTA, DLS, and RPS cannot optimally separate exosomes from non-exosome contaminants; scalability, reproducibility, and regulatory translation also remain challenges.
  • Evident from the text: as a narrative review, it presents no primary experimental data, no systematic quality assessment, and relies on heterogeneous cited models and techniques, so the strength of individual therapeutic claims is not independently evaluated.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics15010021

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The illustration of exosome exchange. Bioactive components can be absorbed into the cell through endocytosis. Vesicle formation is considered to generate early endosomes, which are in turn shaped as MVBs. Part of MVBs could be degraded in lysosomes or through autophagosomes, while other parts could be returned to the plasma membrane and be secreted to the extracellular matrix, forming exosomes.
Figure 1 The illustration of exosome exchange. Bioactive components can be absorbed into the cell through endocytosis. Vesicle formation is considered to generate early endosomes, which are in turn shaped as MVBs. Part of MVBs could be degraded in lysosomes or through autophagosomes, while other parts could be returned to the plasma membrane and be secreted to the extracellular matrix, forming exosomes.CC BY · PubMed Central
Figure 2 The schematic representation of the biological reaction of the protein crown in blood circulation. (A) Various plasma proteins adsorb onto NPs immediately after the synthetic NPs enter the blood, resulting in rapid clearance and cytotoxicity; (B) exosomes weakly bind with the serum proteins, thereby enhancing the circulation time and decreasing the cytotoxicity.
Figure 2 The schematic representation of the biological reaction of the protein crown in blood circulation. (A) Various plasma proteins adsorb onto NPs immediately after the synthetic NPs enter the blood, resulting in rapid clearance and cytotoxicity; (B) exosomes weakly bind with the serum proteins, thereby enhancing the circulation time and decreasing the cytotoxicity.CC BY · PubMed Central
Figure 3 Schematic illustration of the tumor-derived exosomes with modification strategies for enhancing targeting. A chemical or gene modification of extracted exosomes from tumor cells may further promote the anti-tumor functions from indicated concepts.
Figure 3 Schematic illustration of the tumor-derived exosomes with modification strategies for enhancing targeting. A chemical or gene modification of extracted exosomes from tumor cells may further promote the anti-tumor functions from indicated concepts.CC BY · PubMed Central

Verification

Claims the paper makes

108 Not checked yet · 27 No basis given · 23 Own interpretation · 2 Supported · 2 Partly supported · 1 Couldn’t confirm · accuracy not yet measured

Verify all 115 references — free account

Show all 97 claims

  • It may state two separate claims as one. 57
  • Probably not a substantial claim. 14
66 of 66
  • The paper relies on this without support.

    Current studies on heterologous exosomes lack clinical application because of possible immune responses and lack of targeting.

    “Due to the possible immune responses and lack of targeting, current studies on heterologous exosomes lack their clinical application, we mainly reviewed the role of homologous exosomes as drug delivery carriers.”
  • The paper relies on this without support.

    Exosomes from human donor cells are capable of transferring chemical drugs or endogenous substances to receiver cells for therapy.

    “During the exploiting their delivery function, exosomes from human donor cells are found to be capable of transferring chemical drugs or endogenous substances (proteins, mRNAs, miRNAs, lipids, etc.) to receiver cells for therapy.”
  • The paper relies on this without support.

    Therapeutic miRNAs neither penetrate the skin nor easily cross cell membranes.

    “In addition, as carriers, exosomes provide an emerging delivery method for therapeutic miRNAs that neither penetrate the skin nor easily cross cell membranes.”
  • The paper relies on this without support.

    Tumor-derived exosomes contain tumor-associated antigens that can preferably identify tumors.

    “In summary, TDEs contain tumor-associated antigens that can preferably identify tumors and targeted transmit therapeutic substances.”
  • The paper relies on this without support.

    Most research on exosome carriers is still in the in vitro stage.

    “most of the research on exosome carriers is still in the vitro stage”
  • The paper relies on this without support.

    Existing results enhanced the interaction of exosomes with their targets by modifying exosome surface proteins, but did not counteract the natural homing ability of exosomes, nor prevent off-target effects.

    “existing results enhanced the interaction of exosomes with their targets by modifying exosome surface proteins, but they did not counteract the natural homing ability of exosomes, nor did they prevent off-target effects”
  • The paper relies on this without support.

    There is currently a lack of standardized testing for drugs delivered by exosomes.

    “There is currently a lack of standardized testing for drugs delivered by exosomes”
  • The paper relies on this without support.

    There are few studies investigating the ultimate fate of exosomes.

    “few studies investigating the ultimate fate of exosomes”
  • The paper relies on this without support.

    Most previous studies on exosome therapy only involve in vitro models.

    “most of them only involve in vitro models”
  • The paper relies on this without support.

    It is unclear whether previous in vitro results reflect in vivo processes.

    “it is unclear whether these results reflect in vivo processes”
  • The paper relies on this without support.

    Most previous studies simply analyzed a certain number of miRNAs or proteins.

    “most of these studies simply analyzed a certain number of miRNAs or proteins”
  • The paper relies on this without support.

    There is a lack of understanding of exosomes with abundant biological information from distinct cell types.

    “There is a lack of understanding of the exosomes with abundant biological information from distinct cell types”
  • The paper relies on this without support.

    The physical characteristics of exosomes (size, shape, surface charge, density) are necessary to determine their role and function.

    “The physical characteristics of the exosome (including size, shape, surface charge, and density) are necessary to determine its role and function”
  • The paper relies on this without support.

    Challenges remain in reliably tracking exosomes in vivo.

    “challenges remain in reliably tracking exosomes in vivo”
  • The paper relies on this without support.

    The scalability or reproducibility of exosome production is a challenge.

    “the scalability or reproducibility of exosome production is also one of the challenges”
  • The paper relies on this without support.

    Translations of exosomes into clinics are confined within existing regulatory frameworks.

    “the translations of exosomes into clinics are confined within existing regulatory frameworks”
16 of 16

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 131 references

Cited by

Sorted by citations

Metadata

Authors
Li, T., Li, X., Han, G., Liang, M., Yang, Z., Zhang, C., Huang, S., Tai, S., & Yu, S.
Affiliations
  • Harbin Medical University (CN)
  • Second Affiliated Hospital of Harbin Medical University (CN)
Corresponding author
  • Tai, Sheng
  • Yu, Shan
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2022-12-21
Volume
15
Issue
1
Pages
21
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4313469795
Cited by
110
References
131
Citations by year
2026: 28 · 2025: 36 · 2024: 36 · 2023: 10
FWCI
2.13
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Natural Science Foundation of China (81972724)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
exosomes, drug delivery systems, extracellular vesicles, targeted drug delivery, exosome surface modification, cargo loading, intercellular communication, cancer therapy, neurological disorders, immune disorders, bone disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review